000963.SHE Huadong Medicine Co Ltd
- Market cap
- CNY 46.7B
- P/E
- 13.6x
- P/B
- 1.81x
- ROE
- 14.4%
- Dividend yield
- 3.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000963.SHE undervalued?
Graham number000963.SHE trades 4.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Huadong Medicine Co Ltd fundamental analysis
No fundamental analysis for Huadong Medicine Co Ltd yet.
Huadong Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Huadong Medicine Co Ltd
Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. The company operates through Pharmaceutical Manufacturing, Pharmaceutical Distribution, Medical Aesthetics, and Industrial Microbiology segments. It offers Chinese medicine, immunosuppressive agents, endocrine, digestive system, antineoplastic, cardiovascular, antibiotic drugs, medical beauty field, and medical devices, as we…
Full company profileHuadong Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Huadong Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.4B | 27.8B | 30.7B | 35.4B | 33.7B | 34.6B | 37.7B | 40.6B | 41.9B | 43.6B | 44.0B |
| Gross Profit | 6.16B | 7.27B | 8.89B | 11.4B | 11.1B | 10.6B | 12.0B | 13.2B | 13.9B | 14.1B | 14.4B |
| Operating Income | 1.85B | 2.34B | 2.91B | 3.40B | 3.48B | 2.86B | 3.06B | 3.45B | 4.32B | 4.49B | 4.58B |
| EBITDA | 2.13B | 2.56B | 3.20B | 3.59B | 3.46B | 3.32B | 3.78B | 4.32B | 5.09B | 5.13B | 4.43B |
| Net Income | 1.45B | 1.78B | 2.27B | 2.81B | 2.82B | 2.30B | 2.50B | 2.84B | 3.51B | 3.41B | 3.70B |
| EPS | 0.83 | 1.02 | 1.29 | 1.61 | 1.61 | 1.32 | 1.43 | 1.62 | 2.00 | 1.95 | 2.11 |
| Balance Sheet | |||||||||||
| Total Assets | 14.5B | 16.0B | 19.2B | 21.5B | 24.4B | 27.0B | 31.2B | 33.5B | 37.9B | 39.0B | 40.1B |
| Total Liabilities | 6.81B | 7.18B | 8.79B | 8.60B | 9.21B | 10.1B | 12.0B | 11.9B | 14.3B | 13.9B | 14.0B |
| Shareholders' Equity | 7.28B | 8.39B | 9.94B | 12.3B | 14.6B | 16.6B | 18.6B | 21.0B | 23.1B | 24.8B | 25.7B |
| Cash & Short-term Investments | 2.81B | 3.19B | 2.44B | 2.40B | 3.20B | 4.03B | 4.03B | 4.68B | 5.28B | 4.98B | 4.11B |
| Total Debt | 1.48B | 1.37B | 1.66B | 704M | 1.68B | 1.46B | 2.08B | 1.40B | 2.40B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.35B | 1.66B | 2.04B | 2.00B | 3.41B | 3.17B | 2.38B | 3.93B | 3.75B | 4.25B | - |
| Capital Expenditure | 467M | 479M | 876M | 1.35B | 1.47B | 819M | 1.19B | 1.61B | 1.73B | 1.57B | 999M |
| Free Cash Flow | 880M | 1.18B | 1.16B | 648M | 1.94B | 2.35B | 1.19B | 2.32B | 2.02B | 2.67B | 1.48B |
| Ratios | |||||||||||
| ROE | 19.9% | 21.2% | 22.8% | 22.9% | 19.3% | 13.9% | 13.5% | 13.5% | 15.2% | 13.8% | 14.4% |
| ROA | 10.0% | 11.1% | 11.8% | 13.1% | 11.6% | 8.5% | 8.0% | 8.5% | 9.3% | 8.7% | 9.2% |
| Net Profit Margin | 5.7% | 6.4% | 7.4% | 7.9% | 8.4% | 6.7% | 6.6% | 7.0% | 8.4% | 7.8% | 8.4% |
| Debt to Equity | 0.20x | 0.16x | 0.17x | 0.06x | 0.11x | 0.09x | 0.11x | 0.07x | 0.10x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Huadong Medicine Co Ltd dividends
- Dividend yield
- 3.62%
- Forward dividend
- 0.93 CNY
- Payout ratio
- 49.6%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.69B | 0.96 | 49.6% |
| 2024 | CNY 1.70B | 0.97 | 48.5% |
| 2023 | CNY 594M | 0.34 | 20.9% |
| 2022 | CNY 576M | 0.33 | 23.1% |
| 2021 | CNY 460M | 0.26 | 20.0% |
| 2020 | CNY 566M | 0.32 | 20.1% |
| 2019 | CNY 571M | 0.33 | 20.3% |
| 2018 | CNY 769M | 0.44 | 33.9% |
| 2017 | CNY 727M | 0.42 | 40.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 21, 2019.
Who owns Huadong Medicine Co Ltd
- Insiders 58.16%
- Institutions 10.24%
- Public & others 31.61%
- Shares outstanding 1.75B
- Free float 734M
Huadong Medicine Co Ltd company profile
- Company name
- Huadong Medicine Co Ltd
- Ticker
- 000963.SHE
- ISIN
- CNE0000011S1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 22, 1999
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 19,095
- Fiscal year end
- December
- Address
- No. 866 Moganshan Road, Hangzhou, China, 310011
- Phone
- 86 571 8990 3388
- Website
- eastchinapharm.com
About Huadong Medicine Co Ltd
Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. The company operates through Pharmaceutical Manufacturing, Pharmaceutical Distribution, Medical Aesthetics, and Industrial Microbiology segments. It offers Chinese medicine, immunosuppressive agents, endocrine, digestive system, antineoplastic, cardiovascular, antibiotic drugs, medical beauty field, and medical devices, as well as engages in pharmaceutical logistics and industrial microbiology activities. In addition, the company provides formulation filling, technical, transportation and warehousing services. The company has strategic collaboration with Heidelberg Pharma AG to jointly develop Antibody Drug Conjugates (ADCs). Huadong Medicine Co., Ltd was incorporated in 1993 and is headquartered in Hangzhou, China.
Huadong Medicine Co Ltd management
4- Mr. Liang LvChairman & GM · born 1974
- Mr. Renbo QiuCFO & Head of Accounting Department · born 1982
- Mr. Bo ChenSecretary of the Board · born 1972
- Mr. Zhongxing ZhangDeputy General Manager · born 1982